These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17195232)

  • 1. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43.
    Ioannou Y; Pericleous C; Giles I; Latchman DS; Isenberg DA; Rahman A
    Arthritis Rheum; 2007 Jan; 56(1):280-90. PubMed ID: 17195232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies.
    Pericleous C; Miles J; Esposito D; Garza-Garcia A; Driscoll PC; Lambrianides A; Latchman D; Isenberg D; Rahman A; Ioannou Y; Giles I
    Mol Immunol; 2011 Oct; 49(1-2):56-63. PubMed ID: 21899894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli.
    Ioannou Y; Giles I; Lambrianides A; Richardson C; Pearl LH; Latchman DS; Isenberg DA; Rahman A
    BMC Biotechnol; 2006 Feb; 6():8. PubMed ID: 16472380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs.
    Pelkmans L; Kelchtermans H; de Groot PG; Zuily S; Regnault V; Wahl D; Pengo V; de Laat B
    PLoS One; 2013; 8(8):e71402. PubMed ID: 23951154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin.
    Giles IP; Haley J; Nagl S; Latchman DS; Chen PP; Chukwuocha RU; Isenberg DA; Rahman A
    Mol Immunol; 2003 Sep; 40(1):49-60. PubMed ID: 12909130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antiphospholipid antibodies on beta(2) glycoprotein I-phospholipid Interaction.
    Gharavi AE; Cucurull E; Tang H; Silver RM; Branch DW
    Am J Reprod Immunol; 1998 May; 39(5):310-5. PubMed ID: 9602248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies.
    Iverson GM; Reddel S; Victoria EJ; Cockerill KA; Wang YX; Marti-Renom MA; Sali A; Marquis DM; Krilis SA; Linnik MD
    J Immunol; 2002 Dec; 169(12):7097-103. PubMed ID: 12471146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome.
    Ioannou Y; Rahman A
    Lupus; 2010 Apr; 19(4):400-5. PubMed ID: 20353977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope of antiphospholipid antibodies retrieved from peptide microarray based on R39-R43 of β2-glycoprotein I.
    Moghbel M; Roth A; Baptista D; Miteva K; Burger F; Montecucco F; Vuilleumier N; Mach F; Brandt KJ
    Res Pract Thromb Haemost; 2022 Oct; 6(7):e12828. PubMed ID: 36304483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction.
    Chapman J; Soloveichick L; Shavit S; Shoenfeld Y; Korczyn AD
    Clin Dev Immunol; 2005 Sep; 12(3):175-80. PubMed ID: 16295522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept.
    Ioannou Y; Romay-Penabad Z; Pericleous C; Giles I; Papalardo E; Vargas G; Shilagard T; Latchman DS; Isenberg DA; Rahman A; Pierangeli S
    J Thromb Haemost; 2009 May; 7(5):833-42. PubMed ID: 19220729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice.
    Ostertag MV; Liu X; Henderson V; Pierangeli SS
    Lupus; 2006; 15(6):358-65. PubMed ID: 16830882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human beta 2-glycoprotein I.
    George J; Blank M; Gilburd B; Hojnik M; Shenkman B; Tamarin I; Varon D; Matsuura E; Koike T; Shoenfeld Y
    Int Immunol; 1997 Jun; 9(6):913-21. PubMed ID: 9199975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation.
    Rahgozar S; Yang Q; Giannakopoulos B; Yan X; Miyakis S; Krilis SA
    Arthritis Rheum; 2007 Feb; 56(2):605-13. PubMed ID: 17265495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid antibodies differ in aPL cofactor requirement.
    Sammaritano LR; Lockshin MD; Gharavi AE
    Lupus; 1992 Feb; 1(2):83-90. PubMed ID: 1301968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived anti-β2GP1 antibodies recognize a peptide motif pattern and not a specific sequence of residues.
    de Moerloose P; Fickentscher C; Boehlen F; Tiercy JM; Kruithof EKO; Brandt KJ
    Haematologica; 2017 Aug; 102(8):1324-1332. PubMed ID: 28550190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens.
    Giles I; Lambrianides N; Pattni N; Faulkes D; Latchman D; Chen P; Pierangeli S; Isenberg D; Rahman A
    J Immunol; 2006 Aug; 177(3):1729-36. PubMed ID: 16849482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.
    Cabral AR; Amigo MC; Cabiedes J; Alarcon-Segovia D
    Am J Med; 1996 Nov; 101(5):472-81. PubMed ID: 8948270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid syndrome: 30 years and our contribution.
    Koike T
    Int J Rheum Dis; 2015 Feb; 18(2):233-41. PubMed ID: 25524556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.